VolitionRx Expands Investor Relations with LifeSci Advisors' Comprehensive Services

VolitionRx Expands Investor Relations with LifeSci Advisors

VolitionRx Limited, a prominent player in the epigenetics field, has announced a strategic partnership with LifeSci Advisors, a leading life sciences communication agency. This collaboration aims to strengthen Volition's investor relations, particularly as the company embarks on significant operational milestones in the coming year.

Cameron Reynolds, the President and Group CEO of VolitionRx, expressed enthusiasm about this timely partnership, stating, "We warmly welcome LifeSci Advisors at this critical stage in Volition's corporate development." The partnership comes at a time when Volition has achieved noteworthy progress in multiple key areas, especially with the recent launch of its Nu.Q® Vet Cancer Test in clinics across the U.S. and Europe. This development underscores Volition's commitment to enhancing the diagnostic landscape for pets and represents a significant leap in the company's technological capabilities.

Looking ahead to 2025, VolitionRx has set ambitious goals, including achieving multiple financial and operational milestones in both cancer diagnostics and sepsis detection. LifeSci Advisors will be instrumental in amplifying Volition's visibility among institutional investors and family funds that focus on life sciences. By leveraging their extensive network and relationships, LifeSci Advisors aims to accelerate awareness and understanding of Volition's transformative products and solutions.

In addition to this partnership, VolitionRx is poised to participate in the 14th Annual LifeSci Partners Corporate Access Event scheduled for January 15th, 2025, at the Beacon Grand Hotel in San Francisco. This event will coincide with the highly anticipated J.P. Morgan Health Care Conference, providing Volition's management team with an excellent opportunity to connect with investors and key opinion leaders in the healthcare sector.

Volition's management will be available for one-on-one meetings during this event, inviting potential investors and stakeholders to learn more about the company's vision, products, and ongoing projects. To facilitate participation, interested parties can register and book meetings through the LifeSci CAE 2025 portal.

LifeSci Advisors boasts a global footprint, with over 250 employees strategically located in key financial centers such as New York, Boston, London, and Paris. Their comprehensive communication solutions are designed to empower life science companies in effectively engaging with investors, promoting their innovations, and navigating the complex landscape of the healthcare market.

About VolitionRx

VolitionRx is at the forefront of epigenetics, with a mission to revolutionize disease detection methods. The company is dedicated to developing user-friendly, cost-effective blood tests to diagnose and monitor various health conditions, including cancers and diseases linked to NETosis, such as sepsis. By prioritizing early detection and monitoring, VolitionRx aims to enhance patient outcomes and quality of life.

Research and development efforts are centered in Belgium, with innovation labs and offices located in the United States, London, and Singapore. This international presence allows Volition to stay at the cutting edge of biomedical advancements and meet the healthcare needs of diverse populations.

With their recent achievements and forward-looking strategies, VolitionRx is set to make a significant impact in the realm of diagnostics and contribute to advancing healthcare on a global scale. The partnership with LifeSci Advisors marks a key milestone as the company forges ahead toward its ambitious goals in 2025 and beyond.